This drug delayed rheumatoid arthritis for years after treatment ended
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- Abatacept administered for 12 months delayed rheumatoid arthritis onset by up to four years compared with placebo.
- The Lancet Rheumatology published the follow‑up analysis, which tracked 213 high‑risk participants from the UK and Netherlands for four to eight years.
- Professor Andrew Cope of King's College London led the study, noting that early intervention can provide lasting symptom relief and postpone disease even after treatment stops.
- Rheumatoid arthritis currently lacks any approved preventive therapy for high‑risk individuals, affecting about half a million people in the UK.
Why it matters: High‑risk patients gain years of symptom‑free life, reducing disability and healthcare costs, while insurers and employers see lower long‑term expenses, easing the burden on the NHS and improving workforce participation.
